Last reviewed · How we verify
NCT04036188
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
EARLY_PHASE1 trial testing Triamcinolone in Plaque Psoriasis in 24 participants. Currently enrolling.
1 December 2026
Quick facts
| Lead sponsor | Wright State University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 16 October 2019 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Triamcinolone (TRIAMCINOLONE) — full drug profile →
- Vitamin D3 (cholecalciferol) — full drug profile →
- Placebo
Conditions studied
- Plaque Psoriasis — all drugs for Plaque Psoriasis →
- Vitamin D3 — all drugs for Vitamin D3 →
Sponsor
Wright State University
Who can join
18 and older, any sex, with Plaque Psoriasis or Vitamin D3. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Improvement in Psoriasis Area and Severity Score (PASI) from baseline
Time frame: Week 28
Subjects achieving a 50% improvement from baseline (PASI 50) -
Improvement in Investigator Grade Assessment (IGA) from baseline
Time frame: Week 28
Subjects achieving a 1 point reduction from baseline -
Improvement in Body Surface Area (BSA) from baseline
Time frame: Week 28
Subjects achieving a 50% reduction from baseline
Sponsor's own description
These studies are designed to assess the synergistic efficacy of topical 0.1% triamcinolone cream paired with 40,000 IU of oral vitamin D3 daily in treating mild to moderate psoriasis. The study is designed to have all subjects treated with triamcinolone cream (TAC) for 4 weeks, then will be randomized 1:1 into vitamin D3 or placebo for an additional 12 weeks. At that time, the study will become open-label and all subjects will be placed on (or continue) vitamin D3 for an additional 12 weeks. The study will take place over 28 weeks total.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04036188
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Triamcinolone
Trials testing the same drug.
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT06288685 — Percutaneous Trigger Finger Release Concomitant Steroid Injection Versus Percutaneous Trigger Finger Release Alone · Phase 3 · completed
- NCT06032039 — Corticosteroid vs Platelet-Rich Plasma Intra-articular Injections in the Treatment of Knee Osteoarthritis. · EARLY_PHASE1 · unknown
- NCT06004882 — Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for · NA · recruiting
- NCT05992883 — NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis · Phase 3 · recruiting
Other recruiting trials for Plaque Psoriasis
Currently open trials in the same condition.
- NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
- NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
- NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
- NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
- NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting
Other Wright State University trials
Trials by the same sponsor.
- NCT06597123 — AI-Augmented Motivational Interviewing Training for Primary Care · NA · not yet recruiting
- NCT06310200 — Sphenopalatine Ganglion Block and Cold Induced Headaches · Phase 1 · active not recruiting
- NCT06312813 — Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With · Phase 2 · recruiting
- NCT05696964 — Improving Relationships Using Motivational Interviewing · NA · withdrawn
- NCT06663241 — The Validation of New Photographic Technology for Assessing Skin Lesions · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04036188 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wright State University
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04036188.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing